A monoclonal antibody
Pregnancy category AU: B1
Routes of administration-Subcutaneous injection
Bioavailability 82%
Metabolism Proteolysis
Elimination half-life 28 days
Erenumab, sold under the brand name Aimovig, is a medication which blocks the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine, and is administered by subcutaneous injection.
The first CGRPR antagonist to be approved by the U.S. Food and Drug Administration.
Erenumab is indicated for the prevention of migraine in adults.
Side effects: constipation, pruritus, muscle spasms, as well as mild and mostly transient reactions at the injection site.
Erenumab is a fully human monoclonal antibody blocking the calcitonin gene-related peptide receptor (CGRPR).
The medication significantly reduced the number of migraine days per month by 3.2 in the 70-mg group and 3.7 in the 140-mg group, versus 1.8 in the placebo (0-mg) group.